Evergreen Nephrology, a US-based provider of value-based kidney care, has secured $130m in capital financing to expand its care model for patients with kidney disease.
The funding round was led by healthcare investment firms Rubicon Founders and Oak HC/FT and a group of existing investors, joined by K2 HealthVentures.
Evergreen intends to use the financing to expand its operations into new regions.
Also, the company aims to implement new technologies to improve clinical outcomes, simplify care delivery, and reduce the administrative burden on nephrologists.
Rubicon partner and Evergreen Nephrology co-founder partner Matt Kim said: “The healthcare system has long overlooked the critical need to empower nephrologists in the delivery of advanced kidney care management.
“By equipping nephrologists with the tools, resources, and support they need, Evergreen is bridging a crucial gap in healthcare and enabling a more effective, collaborative approach to managing kidney disease.”
Evergreen said its value-based kidney care approach will transform kidney disease management, and its collaborative approach will enhance patient outcomes.
Also, the company partners with nephrologists to provide wraparound support for the patients through its analytical insight and tools, and a dedicated care team.
The team comprises nurse care managers, care coordinators, social workers, dietitians, and pharmacists.
The interdisciplinary model offers holistic and personalised care for patients and allows nephrologists to focus on managing kidney disease, said Evergreen.
Ropes & Gray served as legal counsel to Evergreen in connection with the transaction.
Evergreen Nephrology CEO John Donlan said: “This investment enables us to broaden access to care programs that improve patient outcomes while driving down healthcare costs.
“We are dedicated to creating lasting, positive change for patients and families affected by chronic kidney disease.”
